Yu et al. established that GSK343, a blocker of EZH2 (Table 1), inhibits the proliferation, invasion, and cancer stem-like phenotypes and reverses mesenchymal transition of glioma cells in vitro as well as in vivo [31]. The gene discussed is EZH2; the disease is central nervous system cancer.